1. Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19.
- Author
-
Lu Y, Yang Q, Ran T, Zhang G, Li W, Zhou P, Tang J, Dai M, Zhong J, Chen H, He P, Zhou A, Xue B, Chen J, Zhang J, Yang S, Wu K, Wu X, Tang M, Zhang WK, Guo D, Chen X, Chen H, and Shang J
- Subjects
- Animals, Mice, Humans, Administration, Oral, COVID-19 virology, Protease Inhibitors pharmacology, Protease Inhibitors chemistry, Protease Inhibitors therapeutic use, Coronavirus Papain-Like Proteases antagonists & inhibitors, Coronavirus Papain-Like Proteases metabolism, Coronavirus 3C Proteases antagonists & inhibitors, Coronavirus 3C Proteases metabolism, Chlorocebus aethiops, Vero Cells, Female, Drug Design, Drug Discovery, SARS-CoV-2 drug effects, COVID-19 Drug Treatment, Antiviral Agents pharmacology, Antiviral Agents pharmacokinetics, Antiviral Agents chemistry
- Abstract
The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CL
pro ), and papain-like protease (PLpro ) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CLpro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CLpro from SARS-CoV-2, which makes it necessary to develop antivirals with novel mechanisms. Through the application of a structure-based drug design (SBDD) approach, we discover a series of novel potent non-covalent PLpro inhibitors with remarkable in vitro potency and in vivo PK properties. The co-crystal structures of PLpro with lead compounds reveal that the residues D164 and Q269 around the S2 site are critical for improving the inhibitor's potency. The lead compound GZNL-P36 not only inhibits SARS-CoV-2 and its variants at the cellular level with EC50 ranging from 58.2 nM to 306.2 nM, but also inhibits HCoV-NL63 and HCoV-229E with EC50 of 81.6 nM and 2.66 μM, respectively. Oral administration of the GZNL-P36 results in significantly improved survival and notable reductions in lung viral loads and lesions in SARS-CoV-2 infection mouse model, consistent with RNA-seq data analysis. Our results indicate that PLpro inhibitors represent a promising SARS-CoV-2 therapy., Competing Interests: Competing interests: The authors declare no competing interests., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF